Wordt geladen...
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer
RET receptor tyrosine kinase (RTK) acts as an ontogenetic driver in several human malignancies, including papillary and medullary thyroid carcinoma, lung adenocarcinoma, colorectal carcinoma, Spitzoid neoplasms, salivary gland carcinoma and chronic myeloproliferative disorders, secondary to as diver...
Bewaard in:
| Gepubliceerd in: | Best Pract Res Clin Endocrinol Metab |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5624797/ https://ncbi.nlm.nih.gov/pubmed/28911727 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.beem.2017.04.013 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|